Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule with the molecular formula C42H45N8+ and a molecular weight of approximately 661.9 g/mol[1][2][5]. It features a phenanthridinium core substituted with diamine and phenyl groups as well as an acridinyl-amino triazole-linked hexyl side chain[5]. The structure is related to DNA intercalators and fluorescent dyes but this specific compound is primarily referenced in chemical biology databases as an experimental or research tool rather than a marketed pharmaceutical agent[5][4]. There are no approved medical indications or clinical trial data for therapeutic use; it has been catalogued in DrugBank (DB03005), ChEMBL (CHEMBL540657), and PubChem (CID 5289507/5289508)[5][1][2]. Its mechanism of action has not been explicitly described in public sources but by analogy to similar phenanthridinium derivatives it may act as a DNA intercalator or probe for biochemical assays.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3,8-diamino-6-phenyl-5-[6-[1-[2-[(1,2,3,4-tetrahydro-9-acridinyl)amino]ethyl]-1h-1,2,3-triazol-4-yl]hexyl]-phenanthridinium.